Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

DiaMedica Therapeutics (DMAC) Cash from Financing Activities: 2017-2024

Historic Cash from Financing Activities for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to $12.0 million.

  • DiaMedica Therapeutics' Cash from Financing Activities fell 100.01% to -$1,000 in Q4 2019 from the same period last year, while for Dec 2019 it was $70,000, marking a year-over-year decrease of 99.67%. This contributed to the annual value of $12.0 million for FY2024, which is 67.44% down from last year.
  • According to the latest figures from FY2024, DiaMedica Therapeutics' Cash from Financing Activities is $12.0 million, which was down 67.44% from $36.8 million recorded in FY2023.
  • In the past 5 years, DiaMedica Therapeutics' Cash from Financing Activities ranged from a high of $36.8 million in FY2023 and a low of -$6,000 during FY2022.
  • Its 3-year average for Cash from Financing Activities is $16.3 million, with a median of $12.0 million in 2024.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first plummeted by 100.02% in 2022, then spiked by 614,133.33% in 2023.
  • Over the past 5 years, DiaMedica Therapeutics' Cash from Financing Activities (Yearly) stood at $28.8 million in 2020, then rose by 4.31% to $30.1 million in 2021, then plummeted by 100.02% to -$6,000 in 2022, then surged by 614,133.33% to $36.8 million in 2023, then crashed by 67.44% to $12.0 million in 2024.